Christina A. Bachmeier

1.8k total citations
27 papers, 598 citations indexed

About

Christina A. Bachmeier is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Christina A. Bachmeier has authored 27 papers receiving a total of 598 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 7 papers in Pathology and Forensic Medicine and 5 papers in Genetics. Recurrent topics in Christina A. Bachmeier's work include CAR-T cell therapy research (26 papers), Lymphoma Diagnosis and Treatment (7 papers) and Virus-based gene therapy research (5 papers). Christina A. Bachmeier is often cited by papers focused on CAR-T cell therapy research (26 papers), Lymphoma Diagnosis and Treatment (7 papers) and Virus-based gene therapy research (5 papers). Christina A. Bachmeier collaborates with scholars based in United States, China and Spain. Christina A. Bachmeier's co-authors include Julio C. Chávez, Mohamed A. Kharfan‐Dabaja, Frederick L. Locke, Michael D. Jain, Marco L. Davila, Bhagirathbhai Dholaria, Bijal Shah, Farhad Khimani, Aleksandr Lazaryan and Taiga Nishihori and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Blood.

In The Last Decade

Christina A. Bachmeier

25 papers receiving 590 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christina A. Bachmeier United States	9	518	150	142	129	122	27	598
Jeff Aycock United States	8	589 1.1×	138 0.9×	93 0.7×	155 1.2×	170 1.4×	24	624
Meg Elias United States	6	536 1.0×	128 0.9×	87 0.6×	149 1.2×	151 1.2×	15	568
Gloria Iacoboni Spain	16	588 1.1×	120 0.8×	294 2.1×	102 0.8×	103 0.8×	65	730
Christine Dehner United States	11	402 0.8×	71 0.5×	152 1.1×	88 0.7×	74 0.6×	19	520
Xia Mao China	16	512 1.0×	79 0.5×	84 0.6×	235 1.8×	123 1.0×	66	741
Marika Sherman United States	6	397 0.8×	118 0.8×	53 0.4×	111 0.9×	87 0.7×	12	420
Danielle Vanasse United States	6	507 1.0×	92 0.6×	52 0.4×	189 1.5×	142 1.2×	7	549
Mrinalini Bilgi United States	7	393 0.8×	43 0.3×	170 1.2×	103 0.8×	111 0.9×	9	558
Elizabeth Halton United States	14	555 1.1×	85 0.6×	47 0.3×	117 0.9×	187 1.5×	29	604
Matthew L. Ulrickson United States	8	313 0.6×	53 0.4×	156 1.1×	77 0.6×	66 0.5×	35	401

Countries citing papers authored by Christina A. Bachmeier

Since Specialization

Citations

This map shows the geographic impact of Christina A. Bachmeier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christina A. Bachmeier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christina A. Bachmeier more than expected).

Fields of papers citing papers by Christina A. Bachmeier

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christina A. Bachmeier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christina A. Bachmeier. The network helps show where Christina A. Bachmeier may publish in the future.

Co-authorship network of co-authors of Christina A. Bachmeier

This figure shows the co-authorship network connecting the top 25 collaborators of Christina A. Bachmeier. A scholar is included among the top collaborators of Christina A. Bachmeier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christina A. Bachmeier. Christina A. Bachmeier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Viñal, D., Christina A. Bachmeier, Bijal Shah, et al.. (2023). Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. Transplantation and Cellular Therapy. 29(6). 349.e1–349.e8. 7 indexed citations

Ionescu, Filip, Bijal Shah, Meghan Menges, et al.. (2023). Cladribine and Cyclophosphamide Lymphodepletion Prior to Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma. Blood. 142(Supplement 1). 4884–4884.

Perez, Ariel Perez, Christina A. Bachmeier, Julio C. Chávez, et al.. (2022). Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Advances. 6(13). 3970–3973. 5 indexed citations

Lee, Dae Hyun, Sanjay Chandrasekhar, Michael D. Jain, et al.. (2021). Abstract 9828: Active Surveillance of Cardiotoxicity with Cardiac Biomarkers During Chimeric Antigen Receptor T-Cell Therapy. Circulation. 144(Suppl_1). 2 indexed citations

Alexander, Maurice, Kathryn A. Culos, Julianna Roddy, et al.. (2021). Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration. Transplantation and Cellular Therapy. 27(7). 558–570. 43 indexed citations

Figura, Nicholas, Timothy J. Robinson, Austin J. Sim, et al.. (2021). Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. International Journal of Radiation Oncology*Biology*Physics. 111(5). 1145–1154. 28 indexed citations

Perez, Ariel Perez, Christina A. Bachmeier, Rahul Mhaskar, et al.. (2021). Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Transplantation and Cellular Therapy. 27(9). 768.e1–768.e6. 7 indexed citations

Dean, Erin, Rahul Mhaskar, Hong Lü, et al.. (2020). High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Advances. 4(14). 3268–3276. 146 indexed citations

Perez, Ariel Perez, Christina A. Bachmeier, Aleksandr Lazaryan, et al.. (2020). Factors Affecting Lymphocyte Collection Efficiency and Manufactured Product Specification during Leukapheresis for Diffuse Large B Cell Lymphoma Patients Treated with Commercial Tisagenlecleucel. Blood. 136(Supplement 1). 4–5. 3 indexed citations

10.

Hashmi, Hamza, Abu‐Sayeef Mirza, Anuhya Kommalapati, et al.. (2020). Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Advances. 4(17). 4086–4090. 34 indexed citations

11.

Hashmi, Hamza, Abu‐Sayeef Mirza, Anuhya Kommalapati, et al.. (2020). Incidence and Management of Venous Thrombo-Embolism (VTE) Associated with CD19-Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy: A Single Institution Experience. Biology of Blood and Marrow Transplantation. 26(3). S265–S265. 1 indexed citations

12.

Mirza, Abu‐Sayeef, Ambuj Kumar, Hamza Hashmi, et al.. (2020). Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplantation and Cellular Therapy. 27(3). 242.e1–242.e6. 7 indexed citations

13.

Mokhtari, Sepideh, John A. Arrington, Justin M. Asquith, et al.. (2019). NCMP-13. BRAIN MRI FINDINGS IN PATIENTS TREATED WITH CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) DURING SEVERE NEUROTOXICITY. Neuro-Oncology. 21(Supplement_6). vi181–vi182.

14.

Jain, Michael D., Meghan Menges, Rawan Faramand, et al.. (2019). Tumor Inflammation and Myeloid Derived Suppressor Cells Reduce the Efficacy of CD19 CAR T Cell Therapy in Lymphoma. Blood. 134(Supplement_1). 2885–2885. 9 indexed citations

15.

Faramand, Rawan, Hiroshi Kotani, Dylan Morrissey, et al.. (2019). Prediction of CAR T-Related Toxicities in R/R DLBCL Patients Treated with Axicabtagene Ciloleucel Using Point of Care Cytokine Measurements. Biology of Blood and Marrow Transplantation. 25(3). S408–S409. 5 indexed citations

16.

Kotani, Hiroshi, Rawan Faramand, Sae Bom Lee, et al.. (2019). Prediction of toxicity in R/R DLBCL treated with Axicabtagene Clioleucel (19-28z CAR T). Annals of Oncology. 30. vi82–vi82. 1 indexed citations

17.

Mokhtari, Sepideh, Justin M. Asquith, Christina A. Bachmeier, et al.. (2019). The Use of Intravenous Immunoglobulin (IVIG) during Severe Neurotoxicity Among the Recipients of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy. Blood. 134(Supplement_1). 5627–5627. 1 indexed citations

18.

Logue, Jennifer M., Gabriel Krivenko, Victoria S. Larson, et al.. (2019). Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL).. Journal of Clinical Oncology. 37(15_suppl). e14019–e14019. 3 indexed citations

19.

Jain, Michael D., et al.. (2018). Axicabtagene ciloleucel (KTE-C19), an anti-CD19 CAR T therapy for the treatment of relapsed/refractory aggressive B-cell non-Hodgkin’s lymphoma. Therapeutics and Clinical Risk Management. Volume 14. 1007–1017. 38 indexed citations

20.

Dholaria, Bhagirathbhai, Christina A. Bachmeier, & Frederick L. Locke. (2018). Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities. BioDrugs. 33(1). 45–60. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact